BioMedicure Background

BioMedicure is an emerging biopharmaceutical company dedicated to developing, and producing next generation of products to transform cancer prevention and treatment into eventual cure.

BioMedicure employs the principles of successful vaccines such as Smallpox and Cowpox to develop its cancer vaccine products. These products are cancer cell derivatives that are dead, harmless, non-viable and non-toxic spheres preserving enough antigenic material to transform the immune system into a new one with innate and acquired immune responses to kill pre-cancer cells and cancer cells, including cancer stem cells, specifically.

During a immune response, antigen spheres force lymphocytes to engulf them when administered subcutaneously since they are "foreign" to any immune system. After vaccination, multiple immune responses are induced against pre-cancer cells and cancer cells temporarily and permanently.

Antigenic material in antigen spheres are recognized and memorized by some lymphocytes, such as natural killer (NK) cells and T cytotoxic cells, that may launch immediate attacks against pre-cancer cells and cancer cells with the same antigenic material right away. These immune responses usually last days to a few weeks long.

Professional antigen presentation cells, such as dendritic cells and macrophages, engulf those "foreign" antigen spheres and extract antigens from the antigenic material within the sphere. Self-antigens and antigens are presented through a complicated but coordinated process within a couple of weeks and multiple attacks against specific pre-cancer cells and cancer cells are launched for a long term or permanently. Various immune components including but not limiting to cancer cell specific polyclonal antibodies (for primary and secondary antibody responses), T-memory cells, T-helper cells, T-cytotoxic cells, B-memory cells, B-plasma cells and various interleukins and cytokines.

BioMedicure was funded in 2005 by Dr. Yong Qian, currently the President and CEO. With the support of over 50 investors/shareholders, Dr. Qian's team was able to secure most of BioMedicure's intellectual properties, including but not limiting to enriched cancer stem cells (US patents pending), whole-cell antigen sphere cancer vaccines (US and international patents pending) and Tumorase™ (US TradeMark 3,795,961; US and international patents pending).